1.17 [amount] of 'distributions received from [subsidiary]' is credited to the cost of the investment as a return of capital, not to the parent's profit
UK Company C · an AIM-quoted scientific instruments group · Regulator-style question
In brief
Note 5 reduces the parent's investment in subsidiaries by a 'return of capital' of [amount], described as 'distributions received from [subsidiary] during the year'. IAS 27 paragraph 12 requires a dividend from a subsidiary to be recognised in profit or loss; only a legal return of capital can sensibly reduce cost. The parent's 2025 profit is [amount]; as a dividend the same receipt would have made it [amount]. The report does not say what legal form the distribution took or give a policy for it.
The evidence, as filed
Screenshot withheld to protect the company’s identity: Annual Report 2025, page 104; Annual Report 2025, page 100; Annual Report 2025, page 102. Their wording or layout could lead back to the company even with names and figures masked; the evidence list below records what each page shows.
What the report shows, and what the rule requires
| What the annual report shows | What the rule requires |
|---|---|
| What the annual report shows Note 5: 'Return of capital ([n])' against investments; '[wording masked] [subsidiary] during the year.' Parent profit [n]; parent policies list investments at cost less impairment, with no policy for capital returns. | What the rule requires If the receipt was a dividend: income in the parent's profit ([n]) and an impairment-indicator review under IAS 36 paragraph 12(h); if it was a legal return of capital (reduction of capital or share premium), a statement of that form and of the policy applied. |
What we checked: Parent company balance sheet, statement of changes in equity, policies (note 2) and investments note; Chief Financial Officer's report; search of the whole report for the receipt.
The rule
IAS 27 paragraph 12
Version relied on: UK-adopted international accounting standards (UK Endorsement Board), as in force for financial years beginning in or after January 2025
In separate accounts, a dividend from a subsidiary, joint venture or associate is recognised in profit or loss when the right to receive it is established.
IAS 36 paragraph 12(h)
Version relied on: UK-adopted international accounting standards (UK Endorsement Board), as in force for financial years beginning in or after January 2025
Receiving a dividend from a subsidiary, joint venture or associate is an indicator of impairment in certain circumstances, such as where the dividend exceeds the investee's total comprehensive income.
Why it matters
If the receipt was a dividend, the parent's 2025 profit and realised reserves are understated by [n] and its investment in [subsidiary] is understated by the same amount before any impairment test; if it was a legal capital return, the treatment is acceptable but the form and policy should be stated.
Exposure
A classification question in the parent's own accounts; no penalty is expected unless the answer shows a dividend was misclassified.
Our workings
the parent investment roll-forward shows [n] at [date], a return of capital of ([n]), impairment of ([n]) and [n] at [date]; the note says [wording masked] [subsidiary] during the year'. The parent's profit for the year is [n]. The parent policy states investments 'at cost ... less provision for impairment' and lists the group's dividend and 'other income' policies, neither of which deals with distributions from subsidiaries. The 2024 report put the [subsidiary] investment at [amount] after its impairment.
[n] - [n] - [n] = [n] (the note foots); [n] + [n] = [n] parent profit if the receipt were a dividend. Law and inference: IAS 27 paragraph 12 recognises a dividend from a subsidiary in profit or loss when the right to receive it is established; the pre-2009 rule that deducted pre-acquisition dividends from cost no longer exists, and receiving such a dividend is an impairment indicator under IAS 36 paragraph 12(h). A return of capital effected through a legal reduction of capital is not addressed by IAS 27 and is commonly deducted from cost in practice. The word 'distributions' fits either reading, so the treatment cannot be judged without the legal form. The amount matters because it decides whether [n] is in the parent's profit (and its realised reserves) or reduces the cost of an investment that has just been through an impairment enquiry.
| Item | Computation | Result |
|---|---|---|
| Investment roll-forward 2025 | [n] - [n] - [n] = [n] | foots to the balance sheet |
| Parent profit if the receipt were a dividend | [n] + [n] = [n] | [n] |
Management’s best defence, and our reply
The finance team will say [subsidiary] returned surplus capital by a formal capital reduction, so the receipt was a recovery of the cost of the investment, not income, and deducting it from cost is the accepted UK treatment where IAS 27 is silent. They may add that the alternative would have inflated the parent's profit with an amount that is economically a repayment of the price paid. That is a tenable position, which is why this is a question: the note calls the receipts 'distributions' without saying how they were made, and gives no policy that would let a reader check the treatment.
The fix
- Add to note 5: 'The return of capital of [amount] was effected by a reduction of [subsidiary] [Holding] Limited's [share premium/share capital] and is deducted from the cost of the investment', or, if it was a dividend, recognise it in profit or loss and disclose the IAS 36 paragraph 12(h) assessment.
Question for the company
What legal form did the [amount] of 'distributions received from [subsidiary]' take: a dividend out of [subsidiary]'s profits, or a return of capital through a reduction of share capital or share premium? If a dividend, why is it deducted from the cost of the investment rather than recognised in profit or loss under IAS 27 paragraph 12, and was an impairment-indicator review performed under IAS 36 paragraph 12(h)?
Evidence relied on
| # | What it shows | Type | Where |
|---|---|---|---|
| 1 | [n] deducted from the investment in 2025 | Document | Annual Report 2025, page 104 |
| 2 | The receipt is described as distributions from [subsidiary] | Document | Annual Report 2025, page 104 |
| 3 | Investment [n] at [date] and [n] at [date] | Document | Annual Report 2025, page 104 |
| 4 | 2025 impairment [n] in the same roll-forward | Document | Annual Report 2025, page 104 |
| 5 | Parent profit [n] | Document | Annual Report 2025, page 100 |
| 6 | The only investment policy; nothing on capital returns or subsidiary dividends | Document | Annual Report 2025, page 102 |
Prepared by Pramanex from the company’s published annual reports, without the company’s involvement, to show how an annual report review reads. The company is not named, and nothing on this page is a statement about any identifiable company. Observations are not an audit, review or other assurance engagement, and not legal advice. A regulator-style question is a question, not a conclusion.
Want this on your own annual report, before it is published?
Start with three free findings on your latest published annual report, or talk to us about a fixed-fee pre-publication review.
Your annual report will be in draft before the year-end audit.
Have it read before it is published.
Under NDA, with our reviewer on your insider list under UK MAR.